NIZATIDINE Drug Patent Profile

Which patents cover Nizatidine, and what generic alternatives are available?

Nizatidine is a drug marketed by Ani Pharms, Apotex Inc, Dr Reddys Labs Ltd, Epic Pharma Llc, Glenmark Pharms Inc, Mylan Pharms Inc, Pharmobedient, Watson Labs, and Amneal Pharms. and is included in ten NDAs.

The generic ingredient in NIZATIDINE is nizatidine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nizatidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nizatidine

A generic version of NIZATIDINE was approved as nizatidine by EPIC PHARMA LLC on July 5^th, 2002.

Summary for NIZATIDINE

US Patents:	0
Applicants:	9
NDAs:	10
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	9
Drug Prices:	Drug price information for NIZATIDINE
DailyMed Link:	NIZATIDINE at DailyMed

See drug prices for NIZATIDINE

Recent Clinical Trials for NIZATIDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daewoong Pharmaceutical Co. LTD.	Phase 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1
National Center for Research Resources (NCRR)	Phase 1

See all NIZATIDINE clinical trials

Pharmacology for NIZATIDINE

Drug Class	Histamine-2 Receptor Antagonist
Mechanism of Action	Histamine H2 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for NIZATIDINE

Anti-Ulcer Agents

Histamine H2 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for NIZATIDINE

A02BA	H2-receptor antagonists
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for NIZATIDINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXID	Oral Solution	nizatidine	15 mg/mL	021494	1	2008-05-14

US Patents and Regulatory Information for NIZATIDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	NIZATIDINE	nizatidine	CAPSULE;ORAL	075461-001	Jul 8, 2002		DISCN	No	No
Watson Labs	NIZATIDINE	nizatidine	CAPSULE;ORAL	075616-002	Jul 9, 2002	AB	RX	No	Yes
Dr Reddys Labs Ltd	NIZATIDINE	nizatidine	CAPSULE;ORAL	077314-001	Sep 15, 2005	AB	RX	No	No
Ani Pharms	NIZATIDINE	nizatidine	CAPSULE;ORAL	075668-002	Sep 12, 2002		DISCN	No	No
Glenmark Pharms Inc	NIZATIDINE	nizatidine	CAPSULE;ORAL	090618-002	Jul 15, 2011		DISCN	No	No

Nizatinidine Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Nizatidine, a histamine H2-receptor antagonist, is used to treat peptic ulcers and gastroesophageal reflux disease (GERD). Its market presence is characterized by established generic competition and a mature lifecycle, impacting its current financial trajectory.

What is the global market size and projected growth for nizatidine?

The global market for nizatidine is a mature segment within the broader gastrointestinal drug market. Precise, up-to-date global market size figures are not consistently published by major market research firms due to its generic status and the availability of numerous therapeutic alternatives. However, industry reports indicate a steady but modest market value, estimated to be in the hundreds of millions of USD annually.

Projected growth for nizatidine is expected to remain low, with a compound annual growth rate (CAGR) of approximately 1% to 2% over the next five years. This subdued growth is primarily driven by:

• Genericization: Nizatidine has been off-patent for an extended period, leading to widespread generic availability. This intensifies price competition and limits revenue growth for any single manufacturer.
• Therapeutic Alternatives: The development of proton pump inhibitors (PPIs) like omeprazole, lansoprazole, and pantoprazole has significantly shifted treatment paradigms for GERD and peptic ulcers. PPIs generally offer more potent acid suppression and have become the first-line therapy for many patients.
• Evolving Treatment Guidelines: Updated clinical guidelines increasingly favor PPIs for moderate to severe GERD, further impacting nizatidine's market share.
• Focus on Novel Therapies: Pharmaceutical R&D efforts are increasingly directed towards novel mechanisms of action for gastrointestinal disorders, diverting investment and attention from older drug classes.

Despite these headwinds, nizatidine retains a market presence due to its established safety profile, affordability as a generic option, and continued use in specific patient populations or for milder forms of GERD where PPIs may not be necessary or are contraindicated [1].

Who are the key manufacturers and major market players for nizatidine?

The nizatidine market is dominated by generic pharmaceutical manufacturers. Major players include companies specializing in the production and distribution of off-patent drugs. These entities often have extensive global supply chains and a focus on cost-efficient manufacturing.

Key types of market players include:

• Generic Pharmaceutical Manufacturers: These companies produce nizatidine formulations for various markets. Examples include:
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Mylan N.V. (now part of Viatris)
• Contract Manufacturing Organizations (CMOs): Some companies may utilize CMOs for the production of their nizatidine products.
• Wholesalers and Distributors: These entities play a crucial role in distributing nizatidine products to pharmacies and healthcare providers.

The competitive landscape is highly fragmented, with numerous regional and global players offering nizatidine in various dosage forms (e.g., capsules, oral solutions). Brand loyalty is minimal, and purchasing decisions are largely driven by price and availability.

What is the patent landscape for nizatidine and its impact on market exclusivity?

Nizatidine was originally developed by GlaxoSmithKline (GSK) and patented under various intellectual property rights. The primary composition of matter patent for nizatidine, first filed in the early 1980s, expired decades ago.

Key aspects of the patent landscape:

• Expired Composition of Matter Patents: The core patent covering the nizatidine molecule has long since expired in major global markets, including the United States and Europe. This expiration allowed for the entry of generic manufacturers.
• Limited Post-Patent Exclusivity: While there may have been some secondary patents related to specific formulations, manufacturing processes, or therapeutic uses, these are unlikely to provide significant market exclusivity in the current environment. The economic viability of pursuing such patents for an older drug class is often limited.
• Regulatory Exclusivity: Nizatidine has no current periods of market exclusivity granted by regulatory bodies like the FDA or EMA based on novel drug designations.
• Generic Competition: The absence of patent protection is the primary driver of extensive generic competition. Manufacturers of generic nizatidine can legally produce and market the drug once the foundational patents have expired, leading to price erosion.

The patent landscape for nizatidine is characterized by the complete absence of active market-driving patents. This has resulted in a fully genericized market where intellectual property no longer confers a competitive advantage for market exclusivity.

What are the key regulatory considerations for nizatidine?

The regulatory landscape for nizatidine is primarily governed by the standards for generic drug approval and post-market surveillance. Regulatory bodies worldwide ensure that generic nizatidine products meet stringent standards for safety, efficacy, and quality.

Key regulatory considerations include:

• Abbreviated New Drug Application (ANDA) Pathway: In the United States, generic manufacturers seeking approval for nizatidine must submit an ANDA to the Food and Drug Administration (FDA). This pathway requires demonstrating bioequivalence to the reference listed drug (RLD) without repeating costly clinical trials.
• Bioequivalence Studies: A critical component of the ANDA is the submission of bioequivalence studies, which prove that the generic drug performs in the body in the same way as the RLD.
• Good Manufacturing Practices (GMP): All manufacturing facilities producing nizatidine must adhere to GMP regulations to ensure consistent quality and safety. Regulatory agencies conduct inspections to verify compliance.
• Labeling Requirements: Generic drug labels must include the same warnings, precautions, and indications as the RLD. Any differences must be justified and approved by the regulatory authority.
• Post-Market Surveillance: Once approved, nizatidine products are subject to post-market surveillance. This includes monitoring for adverse events through systems like the FDA's MedWatch program. Manufacturers are responsible for reporting any new safety information.
• Pharmacopeial Standards: Nizatidine products must meet the standards set by official pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.), regarding identity, strength, quality, and purity.
• Orange Book Listings: In the U.S., approved ANDAs for nizatidine are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book), indicating their bioequivalence status.

Regulatory approval processes are standardized for generic drugs, but ongoing compliance with evolving regulations and quality standards is essential for continued market access.

How do nizatidine's pricing and reimbursement dynamics affect its financial performance?

The pricing and reimbursement dynamics for nizatidine are heavily influenced by its generic status and the competitive market environment.

Key factors include:

• Price Erosion due to Competition: The presence of numerous generic manufacturers leads to intense price competition. Prices for nizatidine are significantly lower than those of branded drugs and even other generic medications within the same therapeutic class that have a smaller number of manufacturers.
• Wholesale Acquisition Cost (WAC) and Net Price: The WAC for generic nizatidine is relatively low. After accounting for rebates, discounts, and pharmacy markups, the net price realized by manufacturers is further reduced.
• Reimbursement Policies: Payers, including government programs (e.g., Medicare, Medicaid) and private insurers, generally reimburse for generic nizatidine at established average wholesale prices (AWPs) or their equivalent. They often favor the use of generics due to their cost-effectiveness.
• Preferred Drug Lists and Formularies: While nizatidine is often included on formularies, its use may be subject to prior authorization or step-therapy requirements, particularly if a payer has a preferred PPI on its formulary. However, due to its low cost, it may be a readily available option for less severe indications.
• Patient Copayments: Generic nizatidine typically has very low patient copayments, making it an accessible option for individuals with prescription drug coverage.
• Market Dynamics of Alternatives: The cost and reimbursement of PPIs also indirectly affect nizatidine. If PPIs are significantly more expensive and have stricter reimbursement controls, nizatidine might be chosen for its lower cost and ease of access, despite being less potent.

Overall, the financial performance of nizatidine is characterized by high sales volumes and low profit margins per unit. Companies in this space focus on operational efficiency, supply chain management, and economies of scale to achieve profitability.

What is the clinical utility and therapeutic positioning of nizatidine in current medical practice?

Nizatidine's clinical utility is primarily centered on its role as an H2-receptor antagonist for the treatment of acid-related gastrointestinal disorders. Its therapeutic positioning has evolved significantly with the advent of more potent medications.

Current clinical utility and positioning:

• Treatment of Duodenal and Gastric Ulcers: Nizatidine is effective in healing duodenal ulcers and promoting healing in gastric ulcers. It reduces the production of stomach acid by blocking histamine at H2 receptors in parietal cells.
• Management of Gastroesophageal Reflux Disease (GERD): It is used for the symptomatic relief of heartburn and other GERD symptoms. It can be effective for mild to moderate GERD.
• Prophylaxis of Stress Ulcers: In certain hospitalized patients at risk of developing stress ulcers, nizatidine may be used for prophylaxis.
• Aspiration Pneumonitis Prophylaxis: In some pre-operative settings, nizatidine might be considered to reduce gastric acidity and the risk of aspiration pneumonitis.

Therapeutic positioning:

• Second-line Therapy or for Mild GERD: Due to the superior acid suppression offered by PPIs, nizatidine is often considered a second-line option for GERD or is reserved for patients with milder symptoms.
• Alternative for Patients Intolerant to PPIs: Nizatidine can be an alternative for patients who experience side effects from PPIs or have contraindications to their use.
• Cost-Effective Option: Its low cost makes it a viable option where economic considerations are paramount, or for patients without comprehensive insurance coverage for more expensive alternatives.
• Established Safety Profile: Nizatidine has a long history of use, contributing to a well-understood safety profile. Common side effects are generally mild.

While nizatidine remains a clinically useful drug, its role has shifted from a primary treatment option to a more specialized or cost-driven choice within the acid suppression armamentarium.

What are the key market trends and competitive pressures affecting nizatidine?

The nizatidine market is subject to several overarching trends and competitive pressures that shape its current and future trajectory.

Key market trends:

• Continued Dominance of Generics: The market is entirely genericized, with no prospects for branded resurgence unless novel formulations or combinations emerge with new IP.
• Price Sensitivity: Healthcare systems globally are under pressure to control costs. This drives demand for the lowest-cost generic options, including nizatidine.
• Shift Towards PPIs: The ongoing preference for PPIs in many clinical guidelines for moderate-to-severe GERD and ulcer treatment continues to limit the growth potential for H2 blockers like nizatidine.
• Consolidation in the Generic Sector: The generic pharmaceutical industry has seen significant consolidation. Larger, more efficient players can leverage economies of scale in manufacturing and distribution, increasing pressure on smaller competitors.
• Supply Chain Resilience: Recent global events have highlighted the importance of robust supply chains. Companies with diversified manufacturing bases and reliable sourcing are better positioned.

Competitive pressures:

• Intense Price Competition: This is the most significant pressure. Manufacturers constantly vie for market share through aggressive pricing strategies.
• Manufacturer Agreements and Rebates: Negotiating favorable terms with wholesalers, distributors, and indirectly with pharmacy benefit managers (PBMs) through rebate programs is crucial for market access and profitability.
• Product Quality and Reliability: Maintaining high product quality and ensuring consistent supply are non-negotiable. Recalls or quality issues can severely damage a manufacturer's reputation and market position.
• Competition from Other H2 Blockers: While PPIs are the main competitors, other H2 blockers like ranitidine (though subject to recalls for NDMA contamination) and famotidine also compete within this class.

Companies operating in the nizatidine market must focus on operational excellence, efficient supply chains, and strategic pricing to remain competitive.

What are the financial projections and investment outlook for nizatidine manufacturers?

The financial projections and investment outlook for manufacturers of nizatidine are tied to the dynamics of the generic pharmaceutical market. High-volume, low-margin business models characterize this segment.

Financial projections:

• Stable but Modest Revenue: Revenue is expected to remain stable due to consistent demand for cost-effective gastrointestinal treatments. However, significant revenue growth is not anticipated.
• Profitability Driven by Volume and Efficiency: Profitability relies on achieving significant sales volumes and maintaining highly efficient manufacturing and distribution operations. Cost management is paramount.
• Limited R&D Investment: There is minimal to no investment in novel nizatidine R&D. Any R&D spending would likely focus on process optimization or new generic formulations.
• Cash Flow Generation: Companies with established manufacturing capabilities and market access can generate consistent cash flow from nizatidine sales, which can be reinvested in other product lines or business segments.

Investment outlook:

• Mature and Low-Growth Sector: Investors view the nizatidine market as mature and low-growth. It is not typically a primary driver for investment in innovative pharmaceutical companies.
• Focus on Generic Portfolios: Investment interest is generally directed towards companies with diversified generic portfolios, where nizatidine is one of many products contributing to overall revenue and cash flow.
• Attractive for Niche Generic Players: For companies specializing in high-volume, cost-competitive generics, nizatidine can be a stable contributor. These companies often have expertise in efficient manufacturing and navigating complex supply chains.
• Risk Factors: Key risks for investors include intensified price wars, unexpected regulatory changes, significant supply chain disruptions, or the emergence of even lower-cost alternatives.

The investment outlook is pragmatic, focusing on steady cash flow and operational efficiency rather than significant capital appreciation driven by market expansion for nizatidine itself.

What are the potential future developments or challenges for nizatidine?

The future of nizatidine is likely to be one of continued incremental relevance rather than significant market expansion. Several factors will shape its trajectory.

Potential future developments:

• Sustained Role in Cost-Sensitive Markets: Nizatidine will likely maintain its role in markets where cost is a primary determinant of drug selection and where healthcare budgets are constrained.
• Niche Applications: It may continue to be used for specific patient populations with milder GERD or those intolerant to PPIs, ensuring a baseline level of demand.
• Potential for Combination Therapies (Limited): While unlikely to drive major growth, there's a remote possibility of inclusion in novel fixed-dose combinations if a specific unmet need arises that can be addressed cost-effectively. However, current trends favor novel mechanisms over older drug combinations.

Challenges:

• Continued Erosion of Market Share by PPIs: The trend of PPIs becoming the dominant therapy for GERD is expected to persist, further reducing the market share for H2 blockers.
• Regulatory Scrutiny on Impurities: As seen with ranitidine's N-nitrosodimethylamine (NDMA) contamination, regulatory agencies continue to scrutinize drug impurities. While nizatidine has not faced similar widespread issues, ongoing vigilance and potential future regulatory actions remain a concern.
• Competition from Emerging Therapies: Development of novel therapies for gut health or alternative GERD treatments could further marginalize older drug classes.
• Supply Chain Vulnerabilities: Reliance on global supply chains for active pharmaceutical ingredients (APIs) and finished products presents ongoing risks of disruption due to geopolitical events, trade disputes, or public health crises.
• Pressure to De-list: As healthcare providers and payers optimize formularies for cost and efficacy, drugs with less compelling advantages may face pressure to be removed or de-prioritized.

The future for nizatidine appears to be a gradual decline in its overall therapeutic prominence, offset by its persistent value as an affordable, established option for specific indications and markets.

Key Takeaways

• Nizatidine operates in a mature, fully genericized market with low projected growth (1-2% CAGR), driven by intense price competition and the dominance of PPIs.
• The market is fragmented, populated by numerous generic manufacturers such as Teva, Sun Pharma, and Dr. Reddy's, with profitability hinging on high volumes and operational efficiency.
• All composition of matter patents have expired, eliminating market exclusivity and allowing for continuous generic entry.
• Regulatory compliance focuses on bioequivalence, GMP, and post-market surveillance, with nizatidine products meeting pharmacopeial standards.
• Pricing is highly competitive, leading to low margins per unit, with reimbursement policies generally favoring cost-effective generics.
• Nizatidine's therapeutic positioning has shifted to second-line therapy for GERD, an alternative for PPI-intolerant patients, and a cost-effective option for milder indications.
• Market trends include continued generic dominance, price sensitivity, the persistent shift towards PPIs, and consolidation within the generic sector.
• Financial projections indicate stable but modest revenues and profitability contingent on volume and efficiency, making it an investment in established generic portfolios rather than high-growth opportunities.
• Future challenges include continued market share erosion by PPIs, potential regulatory scrutiny on impurities, and supply chain vulnerabilities, while its role in cost-sensitive markets and for niche applications is expected to continue.

Frequently Asked Questions

1. Will there be any new branded nizatidine products introduced to the market? It is highly unlikely that new branded nizatidine products will be introduced, given the expiration of all fundamental patents and the established presence of generic alternatives. The market opportunity for a new branded entity with limited differentiation is considered negligible.

2. What is the risk of supply shortages for nizatidine? While specific shortages are always possible due to manufacturing issues or API sourcing problems with any drug, nizatidine is produced by numerous generic manufacturers. This broad manufacturing base generally mitigates the risk of widespread, prolonged shortages compared to drugs with fewer suppliers.

3. How does nizatidine compare in efficacy to other H2 blockers like famotidine or cimetidine? In terms of acid suppression, nizatidine is generally considered comparable in efficacy to other H2 blockers like famotidine and cimetidine when used at standard therapeutic doses for conditions like GERD and ulcers. The primary differences lie in their pharmacokinetic profiles, side effect profiles, and potential drug interactions.

4. Are there any specific diagnostic criteria that favor nizatidine over PPIs? Current clinical guidelines generally favor PPIs for moderate to severe GERD or confirmed erosive esophagitis due to their more potent and sustained acid suppression. Nizatidine may be favored for milder, intermittent GERD symptoms where less potent acid suppression is sufficient, or in patients who cannot tolerate PPIs due to side effects or drug interactions. Specific diagnostic criteria do not mandate nizatidine over PPIs in most cases.

5. What is the typical lifespan of a generic drug in the market after patent expiry, and how does nizatidine fit this pattern? A generic drug's lifespan in the market after patent expiry is often decades long, provided there is continued demand and the drug remains therapeutically relevant and cost-effective. Nizatidine exemplifies this, having been available generically for many years and maintaining a presence due to its established profile and affordability, even as newer drug classes have emerged.

Cited Sources

[1] Market Research Future. (2023). Nizatidine Market - Global Research Report Forecast to 2032. Retrieved from https://www.marketresearchfuture.com/reports/nizatidine-market-10594